Investors Buy Large Volume of Put Options on iShares Biotechnology ETF (NASDAQ:IBB)

iShares Biotechnology ETF (NASDAQ:IBB) was the recipient of unusually large options trading on Monday. Traders bought 66,590 put options on the company. This represents an increase of approximately 1,205% compared to the typical daily volume of 5,103 put options.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ:IBB opened at $133.04 on Tuesday. The firm has a 50 day moving average of $144.26 and a 200-day moving average of $141.80. iShares Biotechnology ETF has a 12 month low of $117.28 and a 12 month high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. lifted its stake in shares of iShares Biotechnology ETF by 9.4% in the 1st quarter. Osaic Holdings Inc. now owns 160,173 shares of the financial services provider’s stock valued at $21,985,000 after acquiring an additional 13,777 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in shares of iShares Biotechnology ETF during the first quarter valued at about $436,000. O Shaughnessy Asset Management LLC grew its holdings in shares of iShares Biotechnology ETF by 19.5% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,986 shares of the financial services provider’s stock worth $273,000 after purchasing an additional 324 shares during the last quarter. Boulder Hill Capital Management LP increased its stake in shares of iShares Biotechnology ETF by 211.9% in the first quarter. Boulder Hill Capital Management LP now owns 44,450 shares of the financial services provider’s stock valued at $6,099,000 after buying an additional 30,200 shares during the period. Finally, Wellington Wealth Strategies LLC. bought a new position in iShares Biotechnology ETF in the 1st quarter valued at approximately $452,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.